Advertisement

Investigational New Drugs

, Volume 31, Issue 2, pp 304–319 | Cite as

Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor

  • Anne-Sophie Belzacq-CasagrandeEmail author
  • Florence Bachelot
  • Catherine De Oliveira
  • Séverine Coutadeur
  • Florence Maurier-Mahé
  • Emeline Throo
  • Cédric Chauvignac
  • Laure Pognante
  • Angélique Petibon
  • Thierry Taverne
  • Eric Beausoleil
  • Bertrand Leblond
  • Matthew P. Pando
  • Laurent Désiré
PRECLINICAL STUDIES

Summary

Tumor blood vessels are an important emerging target for anticancer therapy. Here, we characterize the in vitro antiproliferative and antiangiogenic properties of the synthetic small molecule, 7-ethoxy-4-(3,4,5-trimethoxybenzyl)isoquinolin-8-amine dihydrochloride, EHT 6706, a novel microtubule-disrupting agent that targets the colchicine-binding site to inhibit tubulin polymerization. At low nM concentrations, EHT 6706 exhibits highly potent antiproliferative activity on more than 60 human tumor cell lines, even those described as being drug resistant. EHT 6706 also shows strong efficacy as a vascular-disrupting agent, since it prevents endothelial cell tube formation and disrupts pre-established vessels, changes the permeability of endothelial cell monolayers and inhibits endothelial cell migration. Genome-wide transcriptomic analysis of EHT 6706 effects on human endothelial cells shows that the antiangiogenic activity elicits gene deregulations of antiangiogenic pathways. These findings indicate that EHT 6706 is a promising tubulin-binding compound with potentially broad clinical antitumor efficacy.

Keywords

EHT 6706 Tubulin Antiproliferative agent Vascular disrupting agent Microarray transcriptomic analysis 

Notes

Acknowledgements

The authors would like to thank Ms Rachel Carton, Hélène Peillon, and Maud Rochais for technical assistance in the cell proliferation assay and microarray-based transcriptional profiling.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem: Anti-Cancer Agents 2:1–17CrossRefGoogle Scholar
  2. 2.
    Kruczynski A, Hill BT (2001) Vinflunine, the latest vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 40:159–173PubMedCrossRefGoogle Scholar
  3. 3.
    Jordan MA, Thrower D, Wilson L (1991) Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 51:2212–2222PubMedGoogle Scholar
  4. 4.
    Rose WC (1992) Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3:311–321PubMedCrossRefGoogle Scholar
  5. 5.
    Choy H (2001) Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol Hematol 37:237–247PubMedCrossRefGoogle Scholar
  6. 6.
    Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G (1998) Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 5:249–255PubMedGoogle Scholar
  7. 7.
    Berrieman HK, Lind MJ, Cawkwell (2004) Do β-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 5:158–164PubMedCrossRefGoogle Scholar
  8. 8.
    Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumor blood vessels: tubulin-binding agents and the combretastatins. Nat Rev Cancer 5:423–435PubMedCrossRefGoogle Scholar
  9. 9.
    Hasani A, Leighl N (2011) Classification and toxicities of vascular disrupting agents. Clin Lung Cancer 12:18–25PubMedCrossRefGoogle Scholar
  10. 10.
    Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992–3006PubMedCrossRefGoogle Scholar
  11. 11.
    Dachs GU, Steele AJ, Coralli C, Kanthou C, Brooks AC, Gunningham SP, Currie MJ, Watson AI, Robinson BA, Tozer GM (2006) Anti-vascular agent combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 6:280PubMedCrossRefGoogle Scholar
  12. 12.
    Leblond B, Taverne T, Beausoleil E, Chauvignac C, Casagrande AS, Desire L (2011) Substituted isoquinolines and their use as tubulin polymerization inhibitors. Patent number WO2011151423, 2011-12-08Google Scholar
  13. 13.
    Shelanski ML, Gaskin F, Cantor CP (1973) Microtubule assembly in the absence of added nucleotides. Proc Natl Acad Sci U S A 70:765–768PubMedCrossRefGoogle Scholar
  14. 14.
    Lee JC, Timasheff SN (1977) In vitro reconstitution of calf brain microtubules: effects of solution variables. Biochemistry 16:1754–1764PubMedCrossRefGoogle Scholar
  15. 15.
    Tahir SK, Kovar P, Rosenberg SH, Ng SC (2000) Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. Biotechniques 29:156–160PubMedGoogle Scholar
  16. 16.
    Calciano MA, Zhou W, Snyder PJ, Einstein R (2010) Drug treatment of Alzheimer’s disease patients leads to expression changes in peripheral blood cells. Alzheimers Dement 6:386–393PubMedCrossRefGoogle Scholar
  17. 17.
    Zhou W, Calciano M, Jordan H, Brenner M, Johnson S, Wu D, Lei L, Pallares D, Beurdeley P, Rouet F, Gill PS, Bracco L, Soucaille C, Einstein R (2009) High resolution analysis of the human transcriptome: detection of extensive alternative splicing independent of transcriptional activity. BMC Genet 10:63–73PubMedCrossRefGoogle Scholar
  18. 18.
    Kohno K, Kikuchi J, Sato S, Takano H, Saburi Y, Asoh K, Kuwano M (1988) Vincristine-resistant human cancer KB cell line and increased expression of multidrugresistance gene. Jpn J Cancer Res 79:1238–1246PubMedCrossRefGoogle Scholar
  19. 19.
    Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP (1998) Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4:389–398PubMedGoogle Scholar
  20. 20.
    Kim B, Lee S, Suvas S, Rouse BT (2005) Application of plasmid DNA encoding IL-18 diminishes development of herpetic stromal keratitis by antiangiogenic effects. J Immunol 175:509–516PubMedGoogle Scholar
  21. 21.
    Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823PubMedCrossRefGoogle Scholar
  22. 22.
    Kanthou C, Tozer GM (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99:2060–2069PubMedCrossRefGoogle Scholar
  23. 23.
    Kremmidiotis G, Leske AF, Lavranos TC, Beaumont D, Gasic J, Hall A, O'Callaghan M, Matthews CA, Flynn B (2010) BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther 9:1562–1573PubMedCrossRefGoogle Scholar
  24. 24.
    Yokoi A, Kuromitsu J, Kawai T, Nagasu T, Sugi NH, Yoshimatsu K, Yoshino H, Owa T (2002) Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol Cancer Ther 1:275–286PubMedGoogle Scholar
  25. 25.
    Hernández-Vargas H, von Kobbe C, Sánchez-Estévez C, Julián-Tendero M, Palacios J, Moreno-Bueno G (2007) Inhibition of paclitaxel-induced proteasome activation influences paclitaxel cytotoxicity in breast cancer cells in a sequence-dependent manner. Cell Cycle 6:2662–2668PubMedCrossRefGoogle Scholar
  26. 26.
    Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI, Hyun MS (2008) Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep 19:1027–1032PubMedGoogle Scholar
  27. 27.
    Liu S, Xu SW, Kennedy L, Pala D, Chen Y, Eastwood M, Carter DE, Black CM, Abraham DJ, Leask A (2007) FAK is required for TGFbeta-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype. Mol Biol Cell 18:2169–2178PubMedCrossRefGoogle Scholar
  28. 28.
    Scott IC, Blitz IL, Pappano WN, Imamura Y, Clark TG, Steiglitz BM, Thomas CL, Maas SA, Takahara K, Cho KW, Greenspan DS (1999) Mammalian BMP-1/Tolloid-related metalloproteinases, including novel family member mammalian Tolloid-like 2, have differential enzymatic activities and distributions of expression relevant to patterning and skeletogenesis. Dev Biol 213:283–300PubMedCrossRefGoogle Scholar
  29. 29.
    Gonzalez EM, Reed CC, Bix G, Fu J, Zhang Y, Gopalakrishnan B, Greenspan DS, Iozzo RV (2005) BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J Biol Chem 280:7080–7087PubMedCrossRefGoogle Scholar
  30. 30.
    Siemann DW (2002) Vascular targeting agents. Horiz Cancer Ther: From Bench to Bedside 3:4–15. http://www.meniscus.com/horizons/3-2.pdf
  31. 31.
    Kasibhatla S, Gourdeau H, Meerovitch K, Drewe J, Reddy S, Qiu L, Zhang H, Bergeron F, Bouffard D, Yang Q, Herich J, Lamothe S, Cai SX, Tseng B (2004) Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. Mol Cancer Ther 3:1365–1374PubMedGoogle Scholar
  32. 32.
    Hinnen P, Eskens FA (2007) Vascular disrupting agents in clinical development. Br J Cancer 96:1159–1165PubMedCrossRefGoogle Scholar
  33. 33.
    Patterson DM, Rustin GJ (2007) Vascular damaging agents. Clin Oncol 19:443–456CrossRefGoogle Scholar
  34. 34.
    Gridelli C, Rossi A, Maione P, Rossi M, Castaldo V, Sacco PC, Volantuoni C (2009) Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 14:612–620PubMedCrossRefGoogle Scholar
  35. 35.
    Siemann DW, Mercer E, Lepler S, Rojiani AM (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1–6PubMedCrossRefGoogle Scholar
  36. 36.
    Everett AD, Narron JV, StoopsT NH, Tucker A (2004) Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 286:L1194–L1201PubMedCrossRefGoogle Scholar
  37. 37.
    Viñals F, Pouysségur J (2001) Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling. Mol Cell Biol 21:7218–7230PubMedCrossRefGoogle Scholar
  38. 38.
    Huang L, Sankar S, Lin C, Kontos CD, Schroff AD, Cha EH, Feng SM, Li SF, Yu Z, Van Etten RL, Blanar MA, Peters KG (1999) HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity. J Biol Chem 274:38183–38188PubMedCrossRefGoogle Scholar
  39. 39.
    Koo BH, Coe DM, Dixon LJ, Somerville RP, Nelson CM, Wang LW, Young ME, Lindner DJ, Apte SS (2010) ADAMTS9 is a cell-autonomously acting, anti-angiogenic metalloprotease expressed by microvascular endothelial cells. Am J Pathol 176:1494–1504PubMedCrossRefGoogle Scholar
  40. 40.
    Sudhakar A, Nyberg P, Keshamouni VG, Mannam AP, Li J, Sugimoto H, Cosgrove D, Kalluri R (2005) Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest 115:2801–2810PubMedCrossRefGoogle Scholar
  41. 41.
    Bossard C, Berghe LV, Laurell H, Castano C, Cerutti M, Prats AC, Prats H (2004) Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide. Cancer Res 64:7507–7512PubMedCrossRefGoogle Scholar
  42. 42.
    Park MJ, Kwak HJ, Lee HC, Yoo DH, Park IC, Kim MS, Lee SH, Rhee CH, Hong SI (2007) Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor. J Biol Chem 282:30485–30496PubMedCrossRefGoogle Scholar
  43. 43.
    Gagnon ML, Bielenberg DR, Gechtman G, Miao HQ, Takashima S, Soker S, Klagsbrun M (2000) Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci U S A 97:2573–2578PubMedCrossRefGoogle Scholar
  44. 44.
    Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Durden DL, Erdreich-Epstein A, DeClerck YA (2001) Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 61:5587–5594PubMedGoogle Scholar
  45. 45.
    Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH, Jankun J (2001) Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 8:463–470PubMedGoogle Scholar
  46. 46.
    Leali D, Moroni E, Bussolino F, Presta M (2007) Osteopontin overexpression inhibits in vitro re-endothelialization via integrin engagement. J Biol Chem 282:19676–19684PubMedCrossRefGoogle Scholar
  47. 47.
    Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, Machluf M, Neufeld G (2004) Semaphorin-3 F is an inhibitor of tumor angiogenesis. Cancer Res 64:1008–1015PubMedCrossRefGoogle Scholar
  48. 48.
    Singleton PA, Garcia JG, Moss J (2008) Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther 7:1669–1679PubMedCrossRefGoogle Scholar
  49. 49.
    Mishima K, Watabe T, Saito A, Yoshimatsu Y, Imaizumi N, Masui S, Hirashima MP, Morisada T, Oike Y, Araie M, Niwa H, Kubo H, Suda T, Miyazono K (2007) Prox1 induces lymphatic endothelial differentiation via integrin alpha9 and other signaling cascades. Mol Biol Cell 18:1421–1429PubMedCrossRefGoogle Scholar
  50. 50.
    Lay AJ, Jiang XM, Kisker O, Flynn E, Underwood A, Condron R, Hogg PJ (2000) Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 408:869–73PubMedCrossRefGoogle Scholar
  51. 51.
    Bibby DC, Desai J, Chong G, Kremmidiotis G, Wong SS, Leske AF, Matthews CA, Rosen MA, and Rischin D (2011) Functional and molecular biomarker analysis demonstrates pharmacological activity for the novel vascular disrupting agent BNC105 in a first in human clinical study, 23rd Lorne Cancer Conference, 2011Google Scholar
  52. 52.
    Clémenson C, Chargari C, Désiré L, Casagrande AS, Bourhis J, Deutsch E (2012) Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy. Invest New Drugs Jan 14Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Anne-Sophie Belzacq-Casagrande
    • 1
    Email author
  • Florence Bachelot
    • 1
  • Catherine De Oliveira
    • 1
  • Séverine Coutadeur
    • 1
  • Florence Maurier-Mahé
    • 1
  • Emeline Throo
    • 1
  • Cédric Chauvignac
    • 1
  • Laure Pognante
    • 1
  • Angélique Petibon
    • 1
  • Thierry Taverne
    • 1
  • Eric Beausoleil
    • 1
  • Bertrand Leblond
    • 1
  • Matthew P. Pando
    • 1
  • Laurent Désiré
    • 1
  1. 1.Therapeutic DivisionExonhit S.A.ParisFrance

Personalised recommendations